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Abstract. 
Targeted anticancer therapies, unlike the traditional cytotoxic chemotherapies which lead 
to systemic toxicities, frequently cause cutaneous adverse events that are symptomatic and 
manifest in cosmetically sensitive areas. The most common dermatologic toxicities related to 
epidermal growth factor receptor (EGFR) inhibitors are papulopustular eruption, xerosis, pru-
ritus and paronychia. Vascular endothelial growth factor receptor (VEGFR) inhibitors usually 
cause hand-foot skin reaction. Reports of dermatologic side effects such as abnormalities of 
hair growth and mucosal changes also increased.  
These events may contribute to poor adherence, dose interruption and discontinuation of 
the regimens. In addition, psychosocial discomfort causing reduction in the quality of life does 
occur. However, the presence and severity of cutaneous adverse events has shown to have 
positive correlation with treatment response. 
The management of these side effects can be categorized into prophylaxis and reactive 
treatment. Systemic antibiotics and topical corticosteroid could possibly prevent or alleviate 
symptoms caused by EGFR inhibitors. The prevention of sun exposure is recommended to all 
patients on targeted therapy, and emollients and lubricants can be used to relieve and improve 
the hand-foot skin reaction. 
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 中文摘要 
  比起化學治療造成的全身性副作用，抗癌標靶藥物更易引起皮膚反應，而這些副作
用常發生在影響外觀甚鉅的部位。常見的皮膚反應有上皮細胞生長因子受體抑制劑引發
的丘疹樣膿泡型紅疹，乾燥搔癢，以及甲溝炎；血管上皮細胞生長因子受體抑制劑還會
引起手足症候群，除此之外也會發現黏膜及毛髮的變化。這些副作用除了會減低病人使
用標靶治療的意願，也可能使臨床醫師須調整標靶藥物的劑量，甚至導致治療中斷。對
於病人生活品質及心理社會學上都造成不等程度的影響。然而值得注意的是，這些皮膚
反應的發生，可能代表標靶藥物在此類病患是有作用的。 
  皮膚反應的處理可分成預防性及反應性的處理。使用系統性抗生素及外用類固醇藥
膏可能某種程度預防副作用的發生或減緩其症狀。所有接受標靶藥物治療的病人都建議
做好防曬；使用滋潤保養品則可有效減輕手足症候群的症狀。 
 
關鍵字: 標靶治療、皮膚反應、上皮細胞生長因子受體、酪胺酸激酶抑制劑 
INTRODUCTION 
Over the last decade, cancer therapy has increas-
ingly shifted toward targeting specific pathways in-
volved in the pathogenesis of malignancy. The agents 
developed in this effort have improved the ability to 
target cancer cells and the safety profile compared to 
conventional chemotherapies. Despite the benefits, 
treatment with these agents can result in skin adverse 
events that cause discomfort, restrict activities of daily 
living, and may lead to poor treatment adherence, dose 
interruption, and discontinuation of these therapeutic 
regimens [1,2]. Furthermore, these skin adverse events 
can increase overall associated treatment costs [3]. 
Dermatological toxicities are manifested mainly in 
response to treatment with inhibitors of signal trans-
duction proteins including epidermal growth factor 
receptor (EGFR), vascular endothelial growth factor 
(VEGF) and vascular endothelial growth factor re-
ceptor (VEGFR), KIT (or stem cell factor receptor), 
RAF (in the Ras-Raf-MEK-ERK pathway), mamma-
lian target of rapamycin (mTOR, in the PI3K/AKT/ 
mTOR pathway), and cytotoxic T-lymphocyte antigen 
(CTLA) proteins (Table 1). 
Although they are not life -threatening, the cuta-
neous adverse effects resulting from treatment with 
signal transduction protein inhibitors are symptomatic 
and can negatively impact patients’ quality of life 
(QoL) [1]. This article aims to provide an overview of 
the skin toxicities related to cancer target therapy and 
of the current implications for the management of pa-
tients. 
 
CUTANEOUS COMPLICATIONS 
WITH EGFR INHIBITORS 
 
Papulopustular Rash 
Papulopustular rash, also described as acneiform 
eruption, is the earliest and most common cutaneous 
adverse event, which has been reported to occur at 
rates of 50 to 100% in published clinical trials of 
EGFR inhibitors [4]. The pathogenesis is different 
from acne with marked alterations in growth and dif-
ferentiation of the epidermis leading to altered corne-
ocyte terminal differentiation. Transcriptional effects 
induced by EGFR inhibitors, including suppressed  
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expression of genes associated with keratinocyte pro-
liferation, attachment and motility, have also been 
found [5]. The rash usually develops within the first 
weeks of treatment and can occur as early as 2 days 
and as late as 6 weeks after EGFR inhibitor therapy is 
started [6]. Typical presentations are erythematous 
papules and pustules predominately involving sebor-
rheic-rich areas such as the face and upper trunk (Fig-
ure 1). Lesions can be painful and itchy. Comedones, 
which are characteristic of acne, are not seen in pap-
ulopustular rashes [7]. The rash can also involve the 
lower trunk, extremities, and buttocks (Figure 2) [8]. 
Table 1. Summary of targeted therapies and common side effects* 
Molecular target(s) Agent  Class   Cutaneous side effects  Reference
EGFR  Cetuximab mAb  Papulopustular rash 
Xerosis, fissures and pruritus  
Nail and nailfold changes: paronychia,  
pariungual granulation tissue  
Hair changes: Alopecia, hypertrichosis, 
trichomegaly, trichiasis  
In-field radiation toxicity  
4-25 
Panitumumab mAb  
Erlotinib TKI  
Gefitinib TKI 
Afatinib TKI  
VEGFR, PDGFR, 
KIT 
Pazopanib TKI  Hand-foot skin reactions  
Papulopustular rash  
Xerosis, fissures and pruritus  
Nail and nailfold changes: paronychia,  
pariungual granulation tissue 
Alopecia on scalp  
Pazopanib, Sunitinib: gray hair  
9, 11, 26-32, 
43 
VEGFR, PDGFR, 
KIT, RAF 
Sorafenib TKI/STKI 
VEGFR, PDGFR, 
KIT, RET 
Sunitinib TKI  
VEGFR, PDGFR, 
KIT, RET, RAF 
Regorafenib TKI  
RAF  Vemurafenib 
Debrafenib  
STKI  Papulopustular rash  
Hand-foot skin reactions  
Xerosis, fissures and pruritus  
Paronychia  
Keratoacanthoma, cutaneous squamous cell  
carcinoma 
Hyperkeratosis   
32-39 
mTOR  Everolimus 
Temsirolimus 
STKI  Stomatitis/ aphthous ulceration  
Papulopustular rash 
40-42 
CTLA  Ipilimumab  mAb  Bumpy red rash  
Itching  
Vitiligo and gray hair  
57 
*Adapted from Abramson RG, et al. Am J Roentgenol 200: 475-483, 2013. [56]  
CTLA= cytotoxic T-lymphocyte-associated protein, EGFR= epidermal growth factor receptor, KIT= stem-cell factor receptor, mAb=
monoclonal antibody, mTOR= mammalian target of rapamycin, PDGFR= platelet-derived growth factor receptor, STKI= serine-
threonine kinase inhibitior, TKI= tyrosine kinase inhibitor, VEFR= vascular endothelial growth factor, VEGFR= VEGR receptor 
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Figure 1. Typical rapulopustular rash on face in a  
patient taking erlotinib 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Papulopustular rash on buttocks and lower 
limbs in a patient on erlotinib 
 
 
Xerosis and Pruritus 
Xerosis is the second most common skin toxicity 
encountered with EGFR inhibitor use, occurring in 
over 35% of the patients treated with EGFR inhibitors 
in most reports [9-11]. It typically occurs following 
the onset of the papulopustular rash, and presents as 
dry, itchy, scaly patches, which may progress to pain-
ful fissuring and xerotic eczema (Figure 3). Xerosis 
can affect any site, not only areas where papulopus-
tules have developed [11,12].  
 
Nail Abnormalities 
Nail abnormalities are a less common but disturb-
ing side effect of EGFR inhibitor treatment, occurring 
in 24% of those taking panitumumab, 10–15% of pa-
tients on cetuximab, erlotinib and gefitinib, and fewer 
than 1% of patients treated with lapatinib [10,13]. 
These changes, with damage to the nail bed (ony-
cholysis, subungual hemorrhage), nail plate (pigmen-
tary changes, brittle nails), or nail fold (paronychia), 
usually developed after 1-2 months of treatment and 
sometimes not until after 6 months [12,13]. Initially 
presenting with erythema, edema, and tenderness of 
the nail folds, paronychia can affect any fingernail or 
toenail, which often affects routine activities of daily 
living. The inflammation can later progress to painful 
pyogenic granuloma-like lesions over lateral nail fold 
(Figure 4) [15,16]. Local trauma is not a necessary 
condition for the development of the lesions but it 
usually aggravates symptoms of bleeding [17,18]. In 
severe cases, an ingrown nail or periungual abscess 
can occur [15]. 
 
Hair Alterations 
Hair alterations seen with EGFR inhibitor treat-
ment are a late toxicity and usually manifest after 8 
weeks [19]. About 5–30% of patients treated for 6 
months or longer experience alopecia [7]. Alopecia 
tends to occur on the scalp and body. Scalp alopecia is 
typically inflammatory, with both non-scarring and 
scarring forms having been reported (Figure 5) [20,21]. 
Mild hair loss can also be seen on the arms and legs 
[14]. Hair overgrowth, such as hypertrichosis and tri- 
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Figure 3. Xerosis accompanied with pruritus in a  
patient on gefitinib 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Paronychia with granuloma-like tissue on 
the toe of a patient taking gefitinib 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Non-scarring alopecia appeared on a patient 
taking gefitinib 
chomegaly, and hair changes in the texture, growth, or 
curling usually develop 2-5 months after initiating 
EGFR inhibitors [19,22,23]. When these alterations 
occur in the eyelashes, they may lead to corneal irrita-
tion and ultimately ulceration [24,25]. 
 
CUTANEOUS COMPLICATIONS 
WITH MULTIKINASE INHIBITORS 
Similarly to EGFR inhibitors, multi-targeted ki-
nase inhibitors are also associated with a variety of 
different dermatologic adverse effects, including pap-
ulopustular rash, seborrheic dermatitis-like rash, pru-
ritus, alopecia, modification of hair growth, xerosis 
and subungual splinter hemorrhage [26].  
Palmar plantar erythrodysesthesia or hand–foot 
skin reactions (HFSR) are commonly associated with 
multikinase inhibitors targeting VEGFR. Results of 
recent meta-analyses have demonstrated the incidence 
of HFSR to be 19% with sunitinib treatment [27] and 
34% with sorafenib treatment [28]. A higher frequen-
cy of skin and bone marrow toxicities has been noted 
in Asian countries. In Taiwan, for example, a total of 
50% all-grade and 10% grade 3 HFSR has been re-
ported [29]. HFSR often occurs within 6 weeks and 
usually in the first 2 weeks of starting therapy [30]. 
HFSR is characterized by painful blistering plaques or 
by a rash developing on the feet and occasionally on 
the fingertips (Figure 6). This is frequently most se-
vere at pressure points such as the balls of the feet 
(Figure 7) and the fingertips, and therefore may impair 
activities of daily living [27]. The hallmark feature of 
HFSR is localized lesions with hyperkeratosis or blis-
ters, whereas conventional chemotherapy agents, such 
as liposomal doxorubicin, fluorouracil, cytarabine, and 
doxetazel, usually lead to symmetrical erythema and 
edema in the palms and soles [9]. 
The most relevant histopathological indication of 
HFSR is keratinocyte damage, which presents as 
keratinocyte vacuolar degeneration and confluent 
keratinocyte necrosis leading to intraepidermal cleav-
age. Intracytoplasmic eosinophilic bodies resulting 
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Figure 6. Hand-foot skin reaction due to sorafenib manifesting as tender blisters on fingertips 
 
 
from necrotic keratinocytes are unique to this entity 
[9,31]. The pathophysiology of HFSR has not been 
fully recognized. In a recent pioneer study, Yeh et al 
found elevated levels of sunitinib and increased ex-
pression of FasL in the plasma of HFSR patients, and 
their concentrations showed strong correlation with 
one another. The authors demonstrated that plasma of 
HFSR patients caused keratinocyte death and that this 
cytotoxicity could be blocked specifically by an anti- 
FasL antibody. In addition, oral administration of 
sunitinib to mice increased their skin susceptibility to 
mechanical pressure. Their data revealed that Fas/ 
FasL interaction mediates keratinocyte death in 
sunitinib-induced HFSR [32]. 
 
OTHER COMMON SKIN SIDE 
EFFECTS OF TARGET THERAPY 
Development of both benign and malignant epi-
thelial tumors, such as inflammation of actinic kera-
toses, keratoacanthomas and cutaneous squamous cell 
carcinomas, are observed at higher frequencies among 
patients receiving agents that target RAF kinase, in-
cluding sorafenib (6-13.5%) and sunitinib (6.3%) 
[32-36]. These effects are particularly severe and more 
common with the selective BRAF V600E inhibitors 
such as vemurafenib (8-24%) and dabrafenib (6%) 
(Figure 8) [37-39]. In addition to skin tumors, BRAF 
inhibitors can induce exanthema (up to 18%), photo-
sensitivity (12%), alopecia (8%), pruritus (7%) and 
hyperkeratosis (6%) [37]. 
Oral ulcerations, usually forming within 1-2 weeks 
after initiation of therapy, are a common dose-limiting 
toxicity associated with mTOR inhibitors [41,42]. The 
ulcers generally manifest as painful, discrete, ovoid, 
superficial ulcers with a well-defined border, a pe-
ripheral halo of erythema, and a grayish-white pseu-
domembrane on the inner aspect of the lips and ven-
tral surface of the tongue and soft palate. The ulcers 
do not form on gingiva and the dorsal surface of the 
tongue, unlike viral ulcers which normally do affect 
keratinized mucosa [40].  
Involvement of oral mucosa secondary to EGFR 
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Figure 7. Hyperkeratotic plaques with bullae on soles of patient receiving sorafenib therapy 
 
 
inhibitors and multikinase inhibitors has also been 
documented. The clinical presentation reported in-
cludes mild to moderate mucositis, stomatitis, and 
aphthous ulcers, which often resolved without specific 
intervention [11]. Nasal mucosa ulcers induced by 
EGFR inhibitors have been reported as well and ap-
pear to be related to xerosis and bacterial proliferation 
in carriers [42]. Both sorafenib and sunitinib may be 
associated with inflammation of oral mucosa in up to 
45% of patients [26]. In a retrospective analysis, Lee 
et al reported that the onset of stomatitis began before 
the fourth week in patients treated with sunitinib (81%) 
and sorafenib (90%) [43]. 
 
MANAGEMENT 
RECOMMENDATIONS 
Patient education about potential dermatologic 
toxicities before initiation of treatment is an essential 
component of patient care. On initiation of target 
therapy, although evidence in support of this recom-
mendation is lacking, patients are advised to use sun-
screen along with moisturizing cream and gentle 
cleansers [44,45]. Patients should be instructed to 
protect their skin, such as by avoiding constrictive 
footwear, reducing contact with hot water, and wear-
ing gloves and cotton socks to prevent friction or 
trauma to the hands and feet [6,45]. In order to mini-
mize periungual trauma, patients have to trim their 
nails regularly [19]. Areas of pre-existing skin damage 
or hyperkeratosis should be identified and managed 
before the start of treatment [46,47]. 
 
Preemptive Management 
Regarding the papulopustular rash induced by 
cancer target therapy, whether or not to prescribe 
prophylactic oral antibiotics remains controversial. 
The administration of tetracycline antibiotics 50 or 
100 mg twice per day (tetracycline, minocycline, 
doxycline, lymecycline) as preventive therapy has 
been associated with reduced severity of the pap-
ulopustular rash and folliculitis as well as improved 
quality of life (QoL) [48]. Skin toxicity evaluation 
protocol with panitumumab (STEPP) compared effi-
cacy of reactive and prophylactic treatment with pani-
tumumab, both consisting of a skin moisturizer, sun-
screen, 1% hydrocortisone cream, and oral doxycy-
cline. The results showed preemptive management 
improved QoL and led to a reduction greater than 50% 
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Figure 8. Cutaenous squamous cell caricinoma on 
right cheek of a patient on vemurafenib 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The patient taking gefitinib was found to 
have cutaneous candidiasis infection on 
gluteal fold. Scars of previous herpes sim-
plex virus infection were also found (ar-
row) 
 
 
in the rate of skin toxicity in comparison to reactive 
treatment [49]. However, this preemptive management 
did not reduce the incidence of exanthema [48]. 
 
Reactive Management 
The standardized National Cancer Institute’s 
Common Terminology Criteria for Adverse Events 
(NCI-CTCAE) version 4.0 grading for skin toxicities 
(Table 2) is helpful for both oncologists and derma-
tologists in making treatment decisions [50]. Reas-
sessment of the severity of dermatologic adverse 
events every other week in order to adjust their man-
agement is recommended. However, the NCI-CTCAE 
may not completely reflect the dermatologic adverse 
events associated with targeted therapies. The Multi-
national Association of Supportive Care in Cancer’s 
Skin Toxicity Study Group has therefore developed a 
modified grading scale specifically for EGFR inhibi-
tor therapy [51]. 
According to the guidelines for EGFR inhibitor 
therapy, depending on the severity of the papulopus-
tular rash, topical corticosteroids, antibiotics, or oral 
antibiotics can be used to alleviate symptoms [47,52]. 
Low potency topical corticosteroids with or without 
topical antibiotics are recommended for patients with 
rash of grade 1. Typical treatment for acne vulgaris 
may not be beneficial in relieving symptoms caused 
by EGFR inhibitor therapy since the pathophysiology 
involved is different [7]. Addition of oral antibiotics 
twice daily, including doxycycline 100 mg, minocy-
cline 100 mg, or tetracycline 500 mg, should be con-
sidered if the severity is more than grade 2 [45,46,53]. 
Pruritus can adversely affect QoL and sleep [2,6]. 
Oral antihistamines are helpful for their sedative ef-
fects but the symptoms of pruritus are not always re-
lieved. Topical corticosteroids have also been used for 
scalp itch, and they can be prescribed with moisturiz-
ing creams for use once to twice per day to improve 
xerosis [11,12]. In case of refractory eczema or scal-
ing, a direct microscopic examination of scales pre-
pared with potassium hydroxide to identify the pres-
ence of any fungi should be conducted. If fungal in-
fection is detected, additional therapy with antifungal 
agents is recommended (Figure 9). 
Topical agents for inflammatory paronychia in-
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 clude 4% thymol in alcohol, aluminum acetate, corti-
costeroid cream, and intralesional triamcinolone. 
Topical antibiotics or antiseptics can prevent superin-
fection [15]. Oral doxycycline 100 mg once or twice 
daily for 6 weeks may help decrease periungual in-
flammation [53, 54]. Medical intervention, in the form 
of electrocautery, silver nitrate cauterization, or nail 
avulsion, is usually required to remove excessive 
granulation tissue. Although paronychia is often ster-
ile, when increased purulence and pain of the periun-
gual soft tissue occurs, it should be cultured for ap-
propriate antimicrobial selection. The most common 
pathogens are Staphylococcus aureus, Streptococcus, 
Enterococcus, Escherichia coli, Klebsiella, Pseudo-
monas and Candida species [55]. 
Treatment for inflammatory alopecia should start 
early with high-potency topical corticosteroid lotions 
or solutions as first-line therapies [53]. Options for 
epilation include temporary and permanent hair re-
moval such as shaving, eflornithine, waxing, laser, or 
a combination of treatments [46,47,53]. Trichiasis can 
cause corneal ulceration and patients should thus be 
referred to an ophthalmologist for lash clipping or 
further treatment [35,46]. 
Management of HFSR can be started as early as 
the initiation of target therapy, such as by applying 
10% urea cream for moisturization. When treating 
HFSR of grade 1, topical corticosteroids can minimize 
inflammation and also soften thickened hyperkeratotic 
plaques on the hands and feet. For patients with HFSR 
of grade 2 or 3, dose reduction of the target therapy is 
another option for reducing bothersome side effects. 
Non-steroidal anti-inflammatory drugs, such as gam-
ma-aminobutyric acid agonists or narcotics, can also 
be prescribed for pain control [45,46]. 
 
CONCLUSIONS 
Despite many published recommendations, uni-
versal guidelines for managing dermatologic adverse 
conditions resulting from treatment with targeted can-
cer therapy agents are still lacking. Further studies to 
establish standard evidence-based therapies are need-
ed. Studies of regional consensus should be conducted 
in the future as well. 
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